Your browser is no longer supported. Please, upgrade your browser.
Settings
AXSM [NASD]
Axsome Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.70 Insider Own20.99% Shs Outstand37.31M Perf Week-6.40%
Market Cap2.57B Forward P/E- EPS next Y-3.74 Insider Trans0.00% Shs Float29.51M Perf Month-6.32%
Income-98.50M PEG- EPS next Q-0.76 Inst Own66.20% Short Float11.43% Perf Quarter-4.56%
Sales- P/S- EPS this Y-74.40% Inst Trans2.83% Short Ratio10.79 Perf Half Y-9.85%
Book/sh3.63 P/B19.26 EPS next Y-35.00% ROA-48.50% Target Price- Perf Year-20.99%
Cash/sh5.50 P/C12.71 EPS next 5Y- ROE-63.10% 52W Range35.44 - 109.53 Perf YTD-14.16%
Dividend- P/FCF- EPS past 5Y-42.80% ROI- 52W High-35.56% Beta2.53
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low99.15% ATR2.91
Employees45 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)40.62 Volatility4.20% 4.03%
OptionableYes Debt/Eq0.35 EPS Q/Q-10.60% Profit Margin- Rel Volume0.47 Prev Close69.93
ShortableYes LT Debt/Eq0.35 EarningsMar 01 BMO Payout- Avg Volume312.80K Price70.58
Recom1.70 SMA20-2.95% SMA50-8.22% SMA200-7.98% Volume62,916 Change0.93%
Jan-08-21Initiated Jefferies Buy $129
Dec-16-20Initiated Mizuho Buy $120
Sep-29-20Initiated BofA Securities Underperform $66
Sep-10-20Initiated Morgan Stanley Overweight $102
Apr-28-20Reiterated H.C. Wainwright Buy $200 → $210
Apr-14-20Initiated Cowen Outperform $95
Dec-30-19Reiterated H.C. Wainwright Buy $170 → $200
Dec-17-19Reiterated H.C. Wainwright Buy $30 → $170
Dec-16-19Reiterated Guggenheim Buy $65 → $158
Oct-16-19Initiated Guggenheim Buy $48
Sep-18-19Initiated William Blair Outperform
May-28-19Initiated SunTrust Buy
May-23-19Reiterated H.C. Wainwright Buy $23 → $30
Apr-08-19Initiated SVB Leerink Outperform $25
Mar-15-19Reiterated H.C. Wainwright Buy $15 → $18
Oct-03-16Resumed Brean Capital Buy
Dec-15-15Initiated Cantor Fitzgerald Buy
Dec-14-15Initiated Ladenburg Thalmann Buy
Feb-19-21 07:00AM  
Feb-16-21 07:00AM  
Feb-10-21 06:00AM  
Jan-27-21 07:05AM  
Jan-07-21 08:48AM  
Jan-04-21 09:30AM  
Dec-31-20 06:15AM  
06:00AM  
Dec-30-20 12:25AM  
Dec-17-20 05:25PM  
Dec-08-20 06:00AM  
Dec-05-20 11:31AM  
Dec-02-20 06:00AM  
Dec-01-20 06:00AM  
Nov-06-20 11:31PM  
11:30AM  
Nov-05-20 07:00AM  
06:15AM  
Nov-04-20 07:03AM  
07:03AM  
Nov-03-20 07:00AM  
Oct-28-20 07:00AM  
Oct-01-20 11:14AM  
Sep-29-20 12:00PM  
07:00AM  
Sep-24-20 06:00AM  
Sep-22-20 12:19PM  
Sep-21-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 12:46AM  
Sep-14-20 06:00AM  
Sep-10-20 07:00AM  
Sep-09-20 11:30AM  
Sep-08-20 07:00AM  
Sep-03-20 07:00AM  
Aug-31-20 07:00AM  
Aug-28-20 07:00AM  
Aug-20-20 07:00AM  
Aug-11-20 01:05PM  
Aug-10-20 04:44PM  
07:05AM  
07:00AM  
Aug-05-20 07:00AM  
Jul-30-20 07:00AM  
Jul-25-20 07:10AM  
Jul-16-20 12:21PM  
Jul-15-20 01:15PM  
12:05PM  
Jul-14-20 12:16PM  
Jul-13-20 07:00AM  
Jul-08-20 02:41PM  
Jul-07-20 11:14AM  
Jul-03-20 03:19PM  
Jun-29-20 12:49PM  
Jun-26-20 07:00AM  
Jun-15-20 12:24PM  
Jun-07-20 11:30AM  
Jun-04-20 06:27PM  
07:00AM  
May-29-20 01:38PM  
07:00AM  
May-26-20 12:57PM  
07:00AM  
May-23-20 07:36AM  
May-19-20 06:04AM  
May-11-20 11:56AM  
May-09-20 02:00PM  
08:10AM  
06:47AM  
May-08-20 07:00AM  
May-03-20 03:39PM  
Apr-30-20 08:00AM  
07:00AM  
Apr-28-20 11:16AM  
Apr-27-20 06:00AM  
Apr-07-20 12:37PM  
Apr-06-20 06:00AM  
Apr-01-20 01:23PM  
Mar-31-20 05:05PM  
04:52PM  
Mar-30-20 06:00AM  
Mar-29-20 08:53AM  
Mar-28-20 09:23PM  
Mar-23-20 12:17PM  
09:50AM  
Mar-20-20 07:00AM  
Mar-12-20 07:00AM  
Mar-05-20 07:00AM  
Mar-04-20 07:00AM  
Mar-02-20 10:33AM  
Feb-20-20 07:00AM  
Feb-19-20 07:00AM  
Jan-28-20 06:32PM  
Jan-23-20 09:34AM  
Jan-22-20 07:00AM  
Jan-17-20 08:45AM  
Jan-13-20 06:00AM  
Jan-09-20 02:50PM  
Jan-03-20 10:44AM  
08:56AM  
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorJun 29Buy78.5065051,025403,698Jun 30 08:20 AM
Pizzie NickChief Financial OfficerJun 29Buy76.6477759,54941,217Jun 30 08:19 AM